Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
South Asian J Cancer
2017 Jan 01;64:171-175. doi: 10.4103/sajc.sajc_63_17.
Show Gene links
Show Anatomy links
Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India.
Singh R
,
Rohtagi N
.
???displayArticle.abstract???
AIMS: The primary objective of this study was to estimate the clinicopathological and molecular profile of lung cancer patients along with the evaluation of their clinical characteristics at a tertiary care hospital in Northern India.
SUBJECTS AND METHODS: A total of 421 patients with lung cancer histology who were treated at Max Super Speciality Hospitals were included in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and permission was obtained from the Ethics Committee before the start of the study. Clinical characteristics and molecular profiling data were collected from the patient's medical records.
RESULTS: There were 330 (78.4%) men and 91 (21.6%) women with a median age of 62 years (range: 30-93 years). Of the 421 patients, 388 (92.2%) patients had the nonsmall cell lung cancer (NSCLC) histology whereas 33 (7.8%) patients were of SCLC histology. Histology and gender had a significant association with NSCLC and SCLC (P < 0.05). Epidermal growth factor receptor (EGFR) and echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene testing was done in 120 and 93 patients, respectively. Of the 120 patients, 24 (20%) cases were positive for EGFR mutations whereas EML4-ALK fusion gene was present in 8 (8.6%) out of 93 patients.
CONCLUSIONS: Our study confirms the importance of molecular testing in the NSCLC patient subgroup with an aim to identify the exact molecular targets that can benefit from the newer generation of targeted therapies.
Behera,
Lung cancer in India.
2004,
Pubmed
Bilano,
Global trends and projections for tobacco use, 1990-2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control.
2015,
Pubmed
Chen,
[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer: A Network Meta-analysis].
2016,
Pubmed
Chougule,
Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.
2013,
Pubmed
Doval,
Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study.
2013,
Pubmed
Doval,
Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.
2015,
Pubmed
,
Echinobase
Engeland,
The impact of smoking habits on lung cancer risk: 28 years' observation of 26,000 Norwegian men and women.
1996,
Pubmed
Ezzati,
Estimates of global mortality attributable to smoking in 2000.
2003,
Pubmed
Ferlay,
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
2015,
Pubmed
Freedman,
Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study.
2008,
Pubmed
Fry,
The National Cancer Data Base report on lung cancer.
1996,
Pubmed
Früh,
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
2013,
Pubmed
Jemal,
Cancer statistics, 2008.
2008,
Pubmed
Johnson,
Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation.
1990,
Pubmed
Kalemkerian,
Small cell lung cancer.
2013,
Pubmed
Lassen,
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.
1995,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
Moore,
Cancer epidemiology in South Asia - past, present and future.
2010,
Pubmed
Murray,
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.
1993,
Pubmed
NULL,
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.
1995,
Pubmed
Normando,
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.
2015,
Pubmed
Okamoto,
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations.
2010,
Pubmed
Pesch,
Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies.
2012,
Pubmed
Qian,
The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials.
2014,
Pubmed
Reck,
Management of non-small-cell lung cancer: recent developments.
2013,
Pubmed
Rosell,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
2012,
Pubmed
Sahoo,
Screening for EGFR mutations in lung cancer, a report from India.
2011,
Pubmed
Sekine,
Emerging ethnic differences in lung cancer therapy.
2008,
Pubmed
Sequist,
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.
2011,
Pubmed
Siegel,
Cancer statistics, 2013.
2013,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Thankappan,
Tobacco use & social status in Kerala.
2007,
Pubmed
Tsao,
The future of NSCLC: molecular profiles guiding treatment decisions.
2011,
Pubmed
Wong,
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
2009,
Pubmed
,
Echinobase
Zhang,
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
2010,
Pubmed
